GLP-1 Receptor Agonists and Platelet Effects

Mechanism of Action and Platelet Effects

GLP-1 receptor agonists decrease systemic inflammation and platelet aggregation rather than increase platelet counts, according to the American Heart Association 1, 2

GLP-1 receptor agonists have demonstrated cardiovascular benefits, including reduced risk of major adverse cardiovascular events in patients with type 2 diabetes, as recommended by the American Diabetes Association 3
The cardioprotective effects of GLP-1 receptor agonists include improved myocardial substrate utilization, anti-inflammatory and anti-atherosclerotic effects, and reduced myocardial ischemia injury, as stated by the American College of Cardiology 4
GLP-1 receptor agonists improve endothelium-dependent vasodilation, according to the European Society of Cardiology 4, 5

The most common adverse effects of GLP-1 receptor agonists are gastrointestinal, including nausea and vomiting, dyspepsia, diarrhea, gastrointestinal reflux, and constipation, as reported by the American Gastroenterological Association 5, 6
Other documented side effects include cardiac arrhythmia/tachycardia, with a heart rate increase of 3-10 beats/min, as noted by the American Heart Association 2
GLP-1 receptor agonists may cause gallbladder disorders and rare cases of pancreatitis, according to the American Association for the Study of Liver Diseases 4, 5, 6

When monitoring patients on GLP-1 receptor agonists, focus should be on gastrointestinal tolerability, heart rate changes, renal function, and signs of pancreatitis, as recommended by the National Kidney Foundation 1, 3, 4, 5
The American Association of Clinical Endocrinologists suggests that GLP-1 receptor agonists should be used with caution in patients with heart failure with reduced ejection fraction and recent decompensation 1, 7

The American Association of Clinical Endocrinologists recommends that GLP-1 receptor agonists be used cautiously in patients with a history of pancreatitis 4
When initiating GLP-1 receptor agonists, start at a low dose and titrate slowly to minimize gastrointestinal side effects, as advised by the American Gastroenterological Association 4, 5

GLP-1 receptor agonists reduce hepatic fat and steatosis, which can help decrease inflammation associated with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in patients with metabolic disorders 8, 9
The LEAN trial demonstrated that liraglutide led to more frequent resolution of NASH and less progression of fibrosis compared to placebo in patients with NAFLD/NASH 8, 9

GLP-1 receptor agonists reduce epicardial adipose tissue thickness, which is associated with decreased inflammation and improved cardiac outcomes in patients with obesity and type 2 diabetes 10
In patients with obesity and type 2 diabetes, liraglutide treatment resulted in a 36% reduction in epicardial adipose tissue thickness at 6 months 10

GLP-1 receptor agonists may be useful in treating heart failure with preserved ejection fraction (HFpEF) due to their anti-inflammatory effects on epicardial fat 8, 9

The most common adverse effects of GLP-1 receptor agonists are gastrointestinal, including nausea, vomiting, dyspepsia, diarrhea, and constipation 11

The European Association for the Study of the Liver (EASL) recommends GLP-1RAs (semaglutide, liraglutide, dulaglutide) as preferred pharmacological options for treating MASLD/MASH without cirrhosis (F0-F3) according to the 2024 EASL-EASD-EASO clinical practice guidelines 12, 13

For patients with MASLD/MASH without cirrhosis (F0-F3), GLP-1RAs are recommended as first-line pharmacological therapy when locally approved, particularly for those with comorbid type 2 diabetes or obesity 12, 13
For patients with MASLD/MASH with compensated cirrhosis (F4), pharmacotherapy should be individualized with caution, and GLP-1RAs may be considered 14
The American Diabetes Association suggests that GLP-1RAs, such as semaglutide, have the strongest evidence for benefit in patients with NASH and fibrosis 14

Lifestyle modifications remain the cornerstone of MASLD management for all patients, with weight loss goals of ≥5% for steatosis reduction and ≥7-10% for MASH and fibrosis reduction 15, 16
The European Association for the Study of the Liver (EASL) recommends that GLP-1RAs be used as part of a comprehensive approach that includes lifestyle modifications 15, 16